Insulin sensitizer combination therapy for type 2 diabetes

Cyrus V Desouza, V. A. Fonseca

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

To determine whether combination therapy with metformin and a thiazolidinedione was effective treatment for patients with type 2 diabetes mellitus whose primary pathology was insulin resistance, we studied 348 patients for 26 weeks. A combination of metformin and rosiglitazone lowered fasting plasma glucose levels by 52.9 mg/dL and increased the patients' ability to achieve a target glycosylated hemoglobin level of below 7%. Using a combination of metformin and a thiazolidinedione to treat, rather than compensate for, insulin resistance introduces the possibility of addressing issues beyond glycemic control, including cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)11-15
Number of pages5
JournalCardiology Review
Volume18
Issue number1
StatePublished - Feb 10 2001

Fingerprint

Type 2 Diabetes Mellitus
Metformin
Insulin
Insulin Resistance
Aptitude
Glycosylated Hemoglobin A
Fasting
Cardiovascular Diseases
Therapeutics
Pathology
Glucose
2,4-thiazolidinedione
rosiglitazone-metformin combination

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Insulin sensitizer combination therapy for type 2 diabetes. / Desouza, Cyrus V; Fonseca, V. A.

In: Cardiology Review, Vol. 18, No. 1, 10.02.2001, p. 11-15.

Research output: Contribution to journalReview article

Desouza, Cyrus V ; Fonseca, V. A. / Insulin sensitizer combination therapy for type 2 diabetes. In: Cardiology Review. 2001 ; Vol. 18, No. 1. pp. 11-15.
@article{e96addbb1d684a3481437397b6345fd0,
title = "Insulin sensitizer combination therapy for type 2 diabetes",
abstract = "To determine whether combination therapy with metformin and a thiazolidinedione was effective treatment for patients with type 2 diabetes mellitus whose primary pathology was insulin resistance, we studied 348 patients for 26 weeks. A combination of metformin and rosiglitazone lowered fasting plasma glucose levels by 52.9 mg/dL and increased the patients' ability to achieve a target glycosylated hemoglobin level of below 7{\%}. Using a combination of metformin and a thiazolidinedione to treat, rather than compensate for, insulin resistance introduces the possibility of addressing issues beyond glycemic control, including cardiovascular disease.",
author = "Desouza, {Cyrus V} and Fonseca, {V. A.}",
year = "2001",
month = "2",
day = "10",
language = "English (US)",
volume = "18",
pages = "11--15",
journal = "Cardiology Board Review",
issn = "1092-6607",
publisher = "Ascend Media",
number = "1",

}

TY - JOUR

T1 - Insulin sensitizer combination therapy for type 2 diabetes

AU - Desouza, Cyrus V

AU - Fonseca, V. A.

PY - 2001/2/10

Y1 - 2001/2/10

N2 - To determine whether combination therapy with metformin and a thiazolidinedione was effective treatment for patients with type 2 diabetes mellitus whose primary pathology was insulin resistance, we studied 348 patients for 26 weeks. A combination of metformin and rosiglitazone lowered fasting plasma glucose levels by 52.9 mg/dL and increased the patients' ability to achieve a target glycosylated hemoglobin level of below 7%. Using a combination of metformin and a thiazolidinedione to treat, rather than compensate for, insulin resistance introduces the possibility of addressing issues beyond glycemic control, including cardiovascular disease.

AB - To determine whether combination therapy with metformin and a thiazolidinedione was effective treatment for patients with type 2 diabetes mellitus whose primary pathology was insulin resistance, we studied 348 patients for 26 weeks. A combination of metformin and rosiglitazone lowered fasting plasma glucose levels by 52.9 mg/dL and increased the patients' ability to achieve a target glycosylated hemoglobin level of below 7%. Using a combination of metformin and a thiazolidinedione to treat, rather than compensate for, insulin resistance introduces the possibility of addressing issues beyond glycemic control, including cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=0035145243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035145243&partnerID=8YFLogxK

M3 - Review article

VL - 18

SP - 11

EP - 15

JO - Cardiology Board Review

JF - Cardiology Board Review

SN - 1092-6607

IS - 1

ER -